Secukinumab

Novartis on Thursday upped peak sales estimates for two of its key cancer drugs, Kisaqali and Scemblix, which together are now forecast to bring in revenue of at least $14 billion. The upgrade for the two products came alongside the company disclosing new mid-term guidance, which sees annual sales growth in the range of 5% to 6% on a constant currency basis between now and 2030 — previously, growth of 6% annually was expected from 2024 to 2029. CEO Vas Narasimhan said "we expect to sustain…momentum over the next five years, driven by assets we already have in hand as well as upcoming launches with multi-billion-dollar sales potential." According to the drugmaker, it now has eight derisked assets on the market that each have peak sales potential of between $3 billion and $10 billion — Kisqali, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, Fabhalta and Rhapsido. These are forecast to more than offset the impact from generic erosion through 2030, from competition to products such as Cosentyx, Entresto and Tasigna.For Kisqali, peak sales are expected to be at least $10 billion, up from an earlier estimate of $8 billion, while revenue from Scemblix is seen reaching at least $4 billion, lifted from $3 billion previously.Beyond its launched medicines, Novartis said Thursday that it expects at least 15 potentially submission-enabling clinical readouts over the next two years. These include: ianalumab; Ac-PSMA-617; OAV101 IT; pelacarsen; del-desiran and del-brax.

Captor Therapeutics S.A. 13.11.2025 The Hidden Epidemic of Autoimmune Diseases Imagine a life where every day is a struggle against your own body. Bright red patches sharply separate from healthy skin. Swollen, stiff joints that limit movement. Painful, pus-filled lumps under the armpits that cause discomfort and isolation. Constant abdominal pain significantly restricts the quality of life. For millions worldwide, this is the reality of living with autoimmune diseases. Psoriasis is a chronic autoimmune condition in which the immune system attacks the body’s own skin cells. In Poland alone, about one million people are affected, and for many, the disease extends to the joints, leading to psoriatic arthritis. Immune system factors play a central role in the development of psoriasis. It can appear at any age, affecting children, adults, and seniors alike. Hidradenitis Suppurativa (HS), also known as acne inversa, affects up to 1% of the population, making it one of the most stigmatizing skin diseases. On top of that, hundreds of thousands of people suffer from Inflammatory Bowel Diseases (IBD), such as Crohn’s disease. These conditions can lead to complications like fistulas, intestinal strictures, and chronic anemia. IBD is more commonly diagnosed in younger adults. These diseases are not only a source of suffering, they also represent a massive market. For example, sales of just one antibody drug, Cosentyx, reach six billion dollars annually. A Silent Companion: When One Diagnosis Isn’t Enough Autoimmune diseases rarely occur in isolation. For many patients, the diagnosis of psoriasis is just the beginning of a long list of health challenges. Rheumatoid arthritis often follows - the condition causing chronic pain, stiffness, and swelling in the joints, eventually impairing mobility. Joint inflammation can be one of the most disruptive symptoms, affecting daily life and sapping joy. But it doesn’t stop there. Other autoimmune diseases often coexist with psoriasis. Hashimoto’s disease can lead to hypothyroidism, multiple sclerosis attacks the nervous system causing sensory disturbances, muscle weakness, or coordination problems, and type 1 diabetes - though mostly associated with children - can appear in adults alongside other autoimmune conditions. Invisible to others, these symptoms also affect mental health. People with autoimmune diseases are twice as likely to experience depression and anxiety, and stress can worsen their symptoms. Having multiple autoimmune diseases presents not only more symptoms but also a major challenge for doctors - each condition can influence the course and treatment of the others. Patients need to be vigilant for new symptoms and closely monitor their health because a dysregulated immune system can behave unpredictably. Individualized treatment and close collaboration with specialists are crucial. Current Treatments: Effective for the Immune System, Burdensome for Patients The common enemy in these diseases is the body’s own overactive immune system, acting like an army attacking its own territory. Two key “orders to attack” play a central role: interleukin 17A (IL-17A) and 17F (IL-17F). So far, there have been two main treatment approaches: Currently, most autoimmune diseases have no cure. Treatments focus on managing symptoms but have significant limitations. Safe, effective oral drugs that directly address the root cause are nearly nonexistent. Without breakthroughs, these conditions can lead to serious complications and reduced quality of life. A Revolution in a Pill: Smart Treatment Targeting PKC-θ What if we could pack the power and precision of an antibody into a single, convenient tablet? And what if that tablet could be smarter than current drugs? That is exactly what we are developing. Our goal is to develop an oral PKC-θ protein degrader - a completely new approach in the field. Degraders are modern drugs that remove disease-causing proteins. By eliminating PKC-θ, this degrader directly affects T-lymphocytes, the immune cells responsible for the excessive response that drives psoriasis and skin lesions. Penetrating the command center: Instead of intercepting orders like IL-17, the degrader enters the immune cells themselves. Dismantling the factory: Inside the cell, it identifies PKC-θ protein and marks it for destruction, effectively removing the source of the immune “orders.” Dual Advantage: By dismantling the PKC-θ “factory,” production of both IL-17A and IL-17F is stopped, creating a more complete and potent effect than current antibodies. Unlike blocking drugs, this method removes the target protein entirely, representing a modern, highly precise therapy for autoimmune diseases. The Holy Grail: Gut Safety in Autoimmune Disease The greatest benefit of this technology is intestinal safety. The degrader: Calms the “bad” immune cells that produce IL-17 and attack the digestive tract. Supports the “good” regulatory T cells (Tregs), which maintain order in the immune system. Traditional steroid or immunosuppressive drugs can damage the digestive tract and internal organs, especially with long-term use. This new therapy reduces those risks, offering a safer profile. For the first time, there is potential to create a drug that is not only effective for psoriasis, psoriatic arthritis, and Hidradenitis Suppurativa but also safe for the digestive system and potentially curative in IBD, opening access to targeted therapy for millions of patients previously without options. The Role of Oral Degraders in Autoimmune Disease Treatment Autoimmune disease therapies are among the fastest-growing segments of the global pharmaceutical market. Currently, over 5-8% of the world’s population suffers from at least one autoimmune disease, and diagnoses are rising. The global immunological drug market exceeded $110 billion in 2025, with biologics representing a significant portion. Despite their effectiveness, biologics are costly to produce, distribute, and maintain, limiting patient access. This drives the need for cheaper, oral, yet equally effective alternatives. The oral PKC-θ degrader meets these needs, combining the precision of targeted therapy with the convenience and scalability of oral treatment. The potential market includes over 200 million people worldwide. Its ease of use and broad safety profile - especially in gut conditions - could make it the first next-generation oral targeted therapy in this category and reshape the immunology market. The future of autoimmune disease treatment is not just a single tablet a day - it is the combination of power, precision, and safety that can redefine what it means to live with a chronic illness.